In this context, for the first time, we found that GSK343 treatment was able to modulate the innate immune response, increasing CXCL9, CXCL10 and CXCL11 levels in GB, as a result of EZH2 inhibition, enhancing NK cell migration to tumor sites and consequently NK cell-mediated tumor growth inhibition. This evidence concerns the gene CXCL10 and neoplasm.